SEARCH

SEARCH BY CITATION

XII References

  • 1
    Field M, Lohr KN. Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines. Clinical Practice Guidelines: Directions for a New Program. National Academy Press, Washington, DC, 1990.
  • 2
    Cunliffe WJ. The Acnes. Martin Dunitz Ltd, London, 1989.
  • 3
    Cunliffe WJ, Shuster S. Pathogenesis of acne. Lancet 1969; 1: 685687.
  • 4
    Lucky AW, Biro FM, Huster GA, Leach AD, Morrison JA, Ratterman J. Acne vulgaris in premenarchal girls. An early sign of puberty associated with rising levels of dehydroepiandrosterone. Arch Dermatol 1994; 130: 308314.
  • 5
    Burke BM, Cunliffe WJ. The assessment of acne vulgaris – the Leeds technique. Br J Dermatol 1984; 111: 8392.
  • 6
    Orentreich N, Durr NP. The natural evolution of comedones into inflammatory papules and pustules. J Invest Dermatol 1974; 62: 316320.
  • 7
    Lehmann HP, Robinson KA, Andrews JS, Holloway V, Goodman SN. Acne therapy: a methodologic review. J Am Acad Dermatol 2002; 47: 231240.
  • 8
    Barratt H, Hamilton F, Car J, Lyons C, Layton A, Majeed A. Outcome measures in acne vulgaris: systematic review. Br J Dermatol 2009; 160: 132136.
  • 9
    Witkowski JA, Parish LC. The assessment of acne: an evaluation of grading and lesion counting in the measurement of acne. Clin Dermatol 2004; 22: 394397.
  • 10
    Thiboutot D, Gollnick H, Bettoli V et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60: S1S50.
  • 11
    Gollnick H, Cunliffe WJ, Berson D et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49: S1S37.
  • 12
    Gollnick HPM, Finlay AY, Shear N. Can we define acne as a chronic disease? If so, how and when? Am J Clin Dermatol 2008; 9: 279284.
  • 13
    O’brien SC, Lewis JB, Cunliffe WJ. The Leeds revised acne grading system. J Dermatolog Treat 1998; 9: 215220.
  • 14
    Dreno B, Bodokh I, Chivot M et al. [ECLA grading: a system of acne classification for every day dermatological practice]. Ann Dermatol Venereol 1999; 126: 136141.
  • 15
    Dreno B, Alirezai M, Auffret N et al. [Clinical and psychological correlation in acne: use of the ECLA and CADI scales]. Ann Dermatol Venereol 2007; 134: 451455.
  • 16
    Pochi PE, Shalita AR, Strauss JS et al. Report of the Consensus Conference on Acne Classification. Washington, D.C., March 24 and 25, 1990. J Am Acad Dermatol 1991; 24: 495500.
  • 17
    Cook CH, Centner RL, Michaels SE. An acne grading method using photographic standards. Arch Dermatol 1979; 115: 571575.
  • 18
    Pillsbury DM, Shelley WB, Kligman AM. Acne, acneform eruptions and rosacea. In Pillsbury DM, Shelley WB, Kligman AM, eds. Dermatology. Saunders, Philadelphia, 1956: 80048027.
  • 19
    Michaelsson G, Juhlin L, Vahlquist A. Effects of oral zinc and vitamin A in acne. Arch Dermatol 1977; 113: 3136.
  • 20
    Wilson RG. Office application of a new acne grading system. Cutis 1980; 25: 6264.
  • 21
    Allen BS, Smith JG Jr. Various parameters for grading acne vulgaris. Arch Dermatol 1982; 118: 2325.
  • 22
    Layton AM. Disorders of the sebaceous glands. In Burns T, Breathnach S, Cosx N, Griffiths C, eds. Rook’s Textbook of Dermatology, 8th edn. Wiley-Blackwell, Oxford, 2010: 3839.
  • 23
    Tan JK, Tang J, Fung K et al. Development and validation of a comprehensive acne severity scale. J Cutan Med Surg 2007; 11: 211216.
  • 24
    U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry. Acne vulgaris: developing drugs for treatment. 2005. URL http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071292.pdf (last accessed: 4 May 2011).
  • 25
    Simpson NB, Cunliffe WJ. Disorders of the sebaceous glands. In Burns T, Breathnach S, Cosx N, Griffiths C, eds. Rook’s Textbook of Dermatology, 7th edn. Blackwell Science, Oxford, 2004: 43.
  • 26
    Holland DB, Jeremy AH. The role of inflammation in the pathogenesis of acne and acne scarring. Semin Cutan Med Surg 2005; 24: 7983.
  • 27
    Dreno B, Bettoli V, Ochsendorf F et al. An expert view on the treatment of acne with systemic antibiotics and/or oral isotretinoin in the light of the new European recommendations. Eur J Dermatol 2006; 16: 565571.
  • 28
    Layton AM, Henderson CA, Cunliffe WJ. A clinical evaluation of acne scarring and its incidence. Clin Exp Dermatol 1994; 19: 303308.
  • 29
    Pathirana D, Nast A, Ormerod AD et al. On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges. J Eur Acad Dermatol Venereol 2010; 24: 14581467.
  • 30
    Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23(Suppl 2): 170.
  • 31
    GRADE working group. URL http://www.gradeworkinggroup.org/ (last accessed: 2 November 2010).
  • 32
    Amado JM, Matos ME, Abreu AM et al. The prevalence of acne in the north of Portugal. J Eur Acad Dermatol Venereol 2006; 20: 12871295.
  • 33
    Kilkenny M, Merlin K, Plunkett A, Marks R. The prevalence of common skin conditions in Australian school students: 3. acne vulgaris. Br J Dermatol 1998; 139: 840845.
  • 34
    Nijsten T, Rombouts S, Lambert J. Acne is prevalent but use of its treatments is infrequent among adolescents from the general population. J Eur Acad Dermatol Venereol 2007; 21: 163168.
  • 35
    Smithard A, Glazebrook C, Williams HC. Acne prevalence, knowledge about acne and psychological morbidity in mid-adolescence: a community-based study. Br J Dermatol 2001; 145: 274279.
  • 36
    Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol 1999; 41: 577580.
  • 37
    Friedman GD. Twin studies of disease heritability based on medical records: application to acne vulgaris. Acta Genet Med Gemellol (Roma). 1984; 33: 487495.
  • 38
    Dreno B, Poli F. Epidemiology of acne. Dermatology 2003; 206: 710.
  • 39
    Herane MI, Ando I. Acne in infancy and acne genetics. Dermatology 2003; 206: 2428.
  • 40
    Perkins A, Cheng C, Hillebrand G, Miyamoto K, Kimball A. Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian and African American women. J Eur Acad Dermatol Venereol 2010; 25: 10541060.
  • 41
    Cheng CE, Irwin B, Mauriello D, Liang L, Pappert A, Kimball AB. Self-reported acne severity, treatment, and belief patterns across multiple racial and ethnic groups in adolescent students. Pediatr Dermatol 2010; 27: 446452.
  • 42
    Cordain L, Lindeberg S, Hurtado M, Hill K, Eaton SB, Brand-Miller J. Acne vulgaris: a disease of Western civilization. Arch Dermatol 2002; 138: 15841590.
  • 43
    Adebamowo CA, Spiegelman D, Danby FW, Frazier AL, Willett WC, Holmes MD. High school dietary dairy intake and teenage acne. J Am Acad Dermatol 2005; 52: 207214.
  • 44
    Smith RN, Mann NJ, Braue A, Makelainen H, Varigos GA. A low-glycemic-load diet improves symptoms in acne vulgaris patients: a randomized controlled trial. Am J Clin Nutr 2007; 86: 107115.
  • 45
    Katsambas A, Graupe K, Stratigos J. Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Derm Venereol Suppl (Stockh) 1989; 143: 3539.
  • 46
    Iraji F, Sadeghinia A, Shahmoradi Z, Siadat AH, Jooya A. Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris. Indian J Dermatol Venereol Leprol 2007; 73: 9496.
  • 47
    Cunliffe WJ, Holland KT. Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Derm Venereol Suppl (Stockh) 1989; 143: 3134.
  • 48
    Sklar JL, Jacobson C, Rizer R, Gans EH. Evaluation of Triaz 10% Gel and Benzamycin in acne vulgaris. J Dermatolog Treat 1996; 7: 147152.
  • 49
    Hughes BR, Norris JF, Cunliffe WJ. A double-blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clin Exp Dermatol 1992; 17: 165168.
  • 50
    Thiboutot DM, Weiss J, Bucko A et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007; 57: 791799.
  • 51
    Gold LS, Tan J, Cruz-Santana A et al. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis 2009; 84: 110116.
  • 52
    Papageorgiou PP, Chu AC. Chloroxylenol and zinc oxide containing cream (Nels cream) vs. 5% benzoyl peroxide cream in the treatment of acne vulgaris. A double-blind, randomized, controlled trial. Clin Exp Dermatol 2000; 25: 1620.
  • 53
    Hunt MJ, Barnetson RS. A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australas J Dermatol 1992; 33: 131134.
  • 54
    Webster G, Rich P, Gold MH, Mraz S, Calvarese B, Chen D. Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. J Drugs Dermatol 2009; 8: 736743.
  • 55
    Thiboutot D, Zaenglein A, Weiss J, Webster G, Calvarese B, Chen D. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol 2008; 59: 792800.
  • 56
    Lookingbill DP, Chalker DK, Lindholm JS et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 1997; 37: 590595.
  • 57
    Tschen EH, Katz HI, Jones TM et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis 2001; 67: 165169.
  • 58
    Fagundes DS, Fraser JM, Klauda HC. New therapy update – a unique combination formulation in the treatment of inflammatory acne. Cutis 2003; 72: 1619.
  • 59
    Burke B, Eady EA, Cunliffe WJ. Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. Br J Dermatol 1983; 108: 199204.
  • 60
    Gollnick HP, Draelos Z, Glenn MJ et al. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol 2009; 161: 11801189.
  • 61
    Thiboutot D, Pariser DM, Egan N et al. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol 2006; 54: 242250.
  • 62
    Pariser DM, Thiboutot DM, Clark SD, Jones TM, Liu Y, Graeber M. The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: a randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle. Cutis 2005; 76: 145151.
  • 63
    Lucky A, Jorizzo JL, Rodriguez D et al. Efficacy and tolerance of adapalene cream 0.1% compared with its cream vehicle for the treatment of acne vulgaris. Cutis 2001; 68: 3440.
  • 64
    Kawashima M, Harada S, Loesche C, Miyachi Y. Adapalene gel 0.1% is effective and safe for Japanese patients with acne vulgaris: a randomized, multicenter, investigator-blinded, controlled study. J Dermatol Sci 2008; 49: 241248.
  • 65
    Chalker DK, Lesher JL Jr, Smith JG Jr et al. Efficacy of topical isotretinoin 0.05% gel in acne vulgaris: results of a multicenter, double-blind investigation. J Am Acad Dermatol 1987; 17: 251254.
  • 66
    Glass D, Boorman GC, Stables GI, Cunliffe WJ, Goode K. A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris. Dermatology 1999; 199: 242247.
  • 67
    Berger R, Barba A, Fleischer A et al. A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adults. Cutis 2007; 80: 152157.
  • 68
    Christiansen J, Holm P, Reymann F. The retinoic acid derivative Ro 11-1430 in acne vulgaris. A controlled multicenter trial against retinoic acid. Dermatologica 1977; 154: 219227.
  • 69
    Krishnan G. Comparison of two concentrations of tretinoin solution in the topical treatment of acne vulgaris. Practitioner 1976; 216: 106109.
  • 70
    Lucky AW, Cullen SI, Jarratt MT, Quigley JW. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter double-blind, parallel study. J Am Acad Dermatol 1998; 38: S17S23.
  • 71
    Lucky AW, Cullen SI, Funicella T, Jarratt MT, Jones T, Reddick ME. Double-blind, vehicle-controlled, multicenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris. J Am Acad Dermatol 1998; 38: S24S30.
  • 72
    Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol 2006; 54: 7381.
  • 73
    Pedace FJ, Stoughton R. Topical retinoic acid in acne vulgaris. Br J Dermatol 1971; 84: 465469.
  • 74
    Nighland M, Grossman R. Tretinoin microsphere gel in facial acne vulgaris: a meta-analysis. J Drugs Dermatol 2008; 7: s2s8.
  • 75
    Webster G, Cargill DI, Quiring J, Vogelson CT, Slade HB. A combined analysis of 2 randomized clinical studies of tretinoin gel 0.05% for the treatment of acne. Cutis 2009; 83: 146154.
  • 76
    Kuhlman DS, Callen JP. A comparison of clindamycin phosphate 1 percent topical lotion and placebo in the treatment of acne vulgaris. Cutis 1986; 38: 203206.
  • 77
    Lucchina LC, Kollias N, Gillies R et al. Fluorescence photography in the evaluation of acne. J Am Acad Dermatol 1996; 35: 5863.
  • 78
    Rizer RL, Sklar JL, Whiting D, Bucko A, Shavin J, Jarratt M. Clindamycin phosphate 1% gel in acne vulgaris. Adv Ther 2001; 18: 244252.
  • 79
    Shalita AR, Myers JA, Krochmal L, Yaroshinsky A. The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris. J Drugs Dermatol 2005; 4: 4856.
  • 80
    Blaney DJ, Cook CH. Topical use of tetracycline in the treatment of acne: a double-blind study comparing topical and oral tetracycline therapy and placebo. Arch Dermatol 1976; 112: 971973.
  • 81
    Smith JG Jr, Chalker DK, Wehr RF. The effectiveness of topical and oral tetracycline for acne. South Med J 1976; 69: 695697.
  • 82
    Mills O Jr, Thornsberry C, Cardin CW, Smiles KA, Leyden JJ. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol 2002; 82: 260265.
  • 83
    Dobson RL, Belknap BS. Topical erythromycin solution in acne. Results of a multiclinic trial. J Am Acad Dermatol 1980; 3: 478482.
  • 84
    Llorca M, Hernandez-Gill A, Ramos M et al. Erythromycin laurilsulfate in the topical treatment of acne vulgaris. Curr Ther Res 1982; 32: 1420.
  • 85
    Pochi PE, Bagatell FK, Ellis CN et al. Erythromycin 2 percent gel in the treatment of acne vulgaris. Cutis 1988; 41: 132136.
  • 86
    Stinco G, Bragadin G, Trotter D, Pillon B, Patrone P. Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. J Eur Acad Dermatol Venereol 2007; 21: 320325.
  • 87
    do Nascimento LV, Guedes AC, Magalhaes GM, de Faria FA, Guerra RM, de C Almeida F. Single-blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks. J Dermatolog Treat 2003; 14: 166171.
  • 88
    Korkut C, Piskin S. Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. J Dermatol 2005; 32: 169173.
  • 89
    Bucknall JH, Murdoch PN. Comparison of tretinoin solution and benzoyl peroxide lotion in the treatment of acne vulgaris. Curr Med Res Opin 1977; 5: 266268.
  • 90
    Handojo I. The combined use of topical benzoyl peroxide and tretinoin in the treatment of acne vulgaris. Int J Dermatol 1979; 18: 489496.
  • 91
    Lyons RE. Comparative effectiveness of benzoyl peroxide and tretinoin in acne vulgaris. Int J Dermatol 1978; 17: 246251.
  • 92
    Swinyer LJ, Baker MD, Swinyer TA, Mills OH Jr. A comparative study of benzoyl peroxide and clindamycin phosphate for treating acne vulgaris. Br J Dermatol 1988; 119: 615622.
  • 93
    Tucker SB, Tausend R, Cochran R, Flannigan SA. Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. Br J Dermatol 1984; 110: 487492.
  • 94
    Norris JF, Hughes BR, Basey AJ, Cunliffe WJ. A comparison of the effectiveness of topical tetracycline, benzoyl-peroxide gel and oral oxytetracycline in the treatment of acne. Clin Exp Dermatol 1991; 16: 3133.
  • 95
    Gollnick HP, Graupe K, Zaumseil RP. [Azelaic acid 15% gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies]. J Dtsch Dermatol Ges 2004; 2: 841847.
  • 96
    Rietschel RL, Duncan SH. Clindamycin phosphate used in combination with tretinoin in the treatment of acne. Int J Dermatol 1983; 22: 4143.
  • 97
    Thiboutot D, Gold MH, Jarratt MT et al. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis 2001; 68: 1019.
  • 98
    Tu P, Li GQ, Zhu XJ, Zheng J, Wong WZ. A comparison of adapalene gel 0.1% vs. tretinoin gel 0.025% in the treatment of acne vulgaris in China. J Eur Acad Dermatol Venereol 2001; 15(Suppl 3): 3136.
  • 99
    Pierard-Franchimont C, Henry F, Fraiture AL, Fumal I, Pierard GE. Split-face clinical and bio-instrumental comparison of 0.1% adapalene and 0.05% tretinoin in facial acne. Dermatology 1999; 198: 218222.
  • 100
    Cunliffe WJ, Danby FW, Dunlap F, Gold MH, Gratton D, Greenspan A. Randomised, controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris. Eur J Dermatol 2002; 12: 350354.
  • 101
    Cunliffe WJ, Caputo R, Dreno B et al. Efficacy and safety comparison of adapalene (CD271) gel and tretinoin gel in the topical treatment of acne vulgaris. A European multicentre trial. J Dermatolog Treat 1997; 8: 173178.
  • 102
    Ellis CN, Millikan LE, Smith EB et al. Comparison of adapalene 0.1% solution and tretinoin 0.025% gel in the topical treatment of acne vulgaris. Br J Dermatol 1998; 139(Suppl 52): 4147.
  • 103
    Grosshans E, Marks R, Mascaro JM et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol 1998; 139(Suppl 52): 2633.
  • 104
    Shalita A, Weiss JS, Chalker DK et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol 1996; 34: 482485.
  • 105
    Verschoore M, Langner A, Wolska H, Jablonska S, Czernielewski J, Schaefer H. Efficacy and safety of CD 271 alcoholic gels in the topical treatment of acne vulgaris. Br J Dermatol 1991; 124: 368371.
  • 106
    Nyirady J, Grossman RM, Nighland M et al. A comparative trial of two retinoids commonly used in the treatment of acne vulgaris. J Dermatolog Treat 2001; 12: 149157.
  • 107
    Ioannides D, Rigopoulos D, Katsambas A. Topical adapalene gel 0.1% vs. isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial. Br J Dermatol 2002; 147: 523527.
  • 108
    Dominguez J, Hojyo MT, Celayo JL, Dominguez-Soto L, Teixeira F. Topical isotretinoin vs. topical retinoic acid in the treatment of acne vulgaris. Int J Dermatol 1998; 37: 5455.
  • 109
    Leyden JJ, Hickman JG, Jarratt MT, Stewart DM, Levy SF. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg 2001; 5: 3742.
  • 110
    Cunliffe WJ, Holland KT, Bojar R, Levy SF. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002; 24: 11171133.
  • 111
    Kircik L, Green L, Thiboutot D et al. Comparing a novel solubilized benzoyl peroxide gel with benzoyl peroxide/clindamycin: final data from a multicenter, investigator-blind, randomized study. J Drugs Dermatol 2009; 8: 812818.
  • 112
    Tanghetti E, Kircik L, Wilson D, Dhawan S. Solubilized benzoyl peroxide versus benzoyl peroxide/clindamycin in the treatment of moderate acne. J Drugs Dermatol 2008; 7: 534538.
  • 113
    Zouboulis CC, Fischer TC, Wohlrab J, Barnard J, Alio AB. Study of the efficacy, tolerability, and safety of 2 fixed-dose combination gels in the management of acne vulgaris. Cutis 2009; 84: 223229.
  • 114
    Tan J, Gollnick HP, Loesche C, Ma YM, Gold LS. Synergistic efficacy of adapalene 0.1%-benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients. J Dermatolog Treat 2010; 22: 197205.
  • 115
    Gold LS, Cruz A, Eichenfield L et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg. Cutis 2010; 85: 94104.
  • 116
    Kellett N, West F, Finlay AY. Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne. A randomised controlled trial. Br J Dermatol 2006; 154: 524532.
  • 117
    Henderson TA, Olson WH, Leach AD. A single-blind, randomized comparison of erythromycin pledgets and clindamycin lotion in the treatment of mild to moderate facial acne vulgaris. Adv Ther 1995; 12: 172177.
  • 118
    Thielitz A, Helmdach M, Röpke EM, Gollnick H. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol 2001; 145: 1927.
  • 119
    Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%. J Eur Acad Dermatol Venereol 2007; 21: 747753.
  • 120
    Bernstein JE, Shalita AR. Topically applied erythromycin in inflammatory acne vulgaris. J Am Acad Dermatol 1980; 2: 318321.
  • 121
    Hellgren L, Vincent J. Topical erythromycin for acne vulgaris. Dermatologica 1980; 161: 409414.
  • 122
    Jones EL, Crumley AF. Topical erythromycin vs blank vehicle in a multiclinic acne study. Arch Dermatol 1981; 117: 551553.
  • 123
    Lesher JL Jr, Chalker DK, Smith JG Jr et al. An evaluation of a 2% erythromycin ointment in the topical therapy of acne vulgaris. J Am Acad Dermatol 1985; 12: 526531.
  • 124
    Prince RA, Busch DA, Hepler CD, Feldick HG. Clinical trial of topical erythromycin in inflammatory acne. Drug Intell Clin Pharm 1981; 15: 372376.
  • 125
    Rivkin L, Rapaport M. Clinical evaluation of a new erythromycin solution for acne vulgaris. Cutis 1980; 25: 552555.
  • 126
    Alirezai M, Gerlach B, Horvath A, Forsea D, Briantais P, Guyomar M. Results of a randomised, multicentre study comparing a new water-based gel of clindamycin 1% versus clindamycin 1% topical solution in the treatment of acne vulgaris. Eur J Dermatol 2005; 15: 274278.
  • 127
    Braathen LR. Topical clindamycin versus oral tetracycline and placebo in acne vulgaris. Scand J Infect Dis Suppl 1984; 43: 7175.
  • 128
    Gratton D, Raymond GP, Guertin-Larochelle S et al. Topical clindamycin versus systemic tetracycline in the treatment of acne. Results of a multiclinic trial. J Am Acad Dermatol 1982; 7: 5053.
  • 129
    Becker LE, Bergstresser PR, Whiting DA et al. Topical clindamycin therapy for acne vulgaris. A cooperative clinical study. Arch Dermatol 1981; 117: 482485.
  • 130
    Ellis CN, Gammon WR, Stone DZ, Heezen-Wehner JL. A comparison of Cleocin T Solution, Cleocin T Gel, and placebo in the treatment of acne vulgaris. Cutis 1988; 42: 245247.
  • 131
    McKenzie MW, Beck DC, Popovich NG. Topical clindamycin formulations for the treatment of acne vulgaris. An evaluation. Arch Dermatol 1981; 117: 630634.
  • 132
    Petersen MJ, Krusinski PA, Krueger GG. Evaluation of 1% clindamycin phosphate lotion in the treatment of acne. Curr Ther Res 1986; 40: 232238.
  • 133
    Leyden JJ, Wortzman M. A novel gel formulation of clindamycin phosphate-tretinoin is not associated with acne flaring. Cutis 2008; 82: 151156.
  • 134
    Anderson RL, Cook CH, Smith DE. The effect of oral and topical tetracycline on acne severity and on surface lipid composition. J Invest Dermatol 1976; 66: 172177.
  • 135
    Kurokawa I, Akamatsu H, Nishijima S, Asada Y, Kawabata S. Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base. J Am Acad Dermatol 1991; 25: 674681.
  • 136
    Ellis CN, Leyden J, Katz HI et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis 2001; 67: 1320.
  • 137
    Ede M. A double-blind, comparative study of benzoyl peroxide, benzoyl peroxide-chlorhydroxyquinoline, benzoyl peroxide-chlorhydroxyquinoline-hydrocortisone, and placebo lotions in acne. Curr Ther Res Clin Exp 1973; 15: 624629.
  • 138
    Jaffe GV, Grimshaw JJ, Constad D. Benzoyl peroxide in the treatment of acne vulgaris: a double-blind, multi-centre comparative study of ‘Quinoderm’ cream and ‘Quinoderm’ cream with hydrocortisone versus their base vehicle alone and a benzoyl peroxide only gel preparation. Curr Med Res Opin 1989; 11: 453462.
  • 139
    Mills OH Jr, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol 1986; 25: 664667.
  • 140
    Smith EB, Padilla RS, McCabe JM, Becker LE. Benzoyl peroxide lotion (20 percent) in acne. Cutis 1980; 25: 9092.
  • 141
    Langner A, Boorman GC, Stapor V. Isotretinoin cream 0.05% and 0.1% in the treatment of acne vulgaris. J Dermatol Treat 1994; 5: 177180.
  • 142
    Webster GF. Safety and efficacy of Tretin-X compared with Retin-A in patients with mild-to-severe acne vulgaris. Skinmed 2006; 5: 114118.
  • 143
    Mills OH Jr, Kligman AM. Treatment of acne vulgaris with topically applied erythromycin and tretinoin. Acta Derm Venereol 1978; 58: 555557.
  • 144
    Cavicchini S, Caputo R. Long-term treatment of acne with 20% azelaic acid cream. Acta Derm Venereol Suppl (Stockh) 1989; 143: 4044.
  • 145
    Handojo I. Retinoic acid cream (Airol cream) and benzoyl-peroxide in the treatment of acne vulgaris. Southeast Asian J Trop Med Public Health 1979; 10: 548551.
  • 146
    Zhu XJ, Tu P, Zhen J, Duan YQ. Adapalene gel 0.1%: effective and well tolerated in the topical treatment of acne vulgaris in Chinese patients. Cutis 2001; 68: 5559.
  • 147
    Leyden JJ, Berger RS, Dunlap FE, Ellis CN, Connolly MA, Levy SF. Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. Am J Clin Dermatol 2001; 2: 3339.
  • 148
    Bojar RA, Eady EA, Jones CE, Cunliffe WJ, Holland KT. Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br J Dermatol 1994; 130: 329336.
  • 149
    Habbema L, Koopmans B, Menke HE, Doornweerd S, De Boulle K. A 4% erythromycin and zinc combination (Zineryt) versus 2% erythromycin (Eryderm) in acne vulgaris: a randomized, double-blind comparative study. Br J Dermatol 1989; 121: 497502.
  • 150
    Stoughton RB, Cornell RC, Gange RW, Walter JF. Double-blind comparison of topical 1 percent clindamycin phosphate (Cleocin T) and oral tetracycline 500 mg/day in the treatment of acne vulgaris. Cutis 1980; 26: 424425, 429.
  • 151
    Rapaport M, Puhvel SM, Reisner RM. Evaluation of topical erythromycin and oral tetracycline in acne vulgaris. Cutis 1982; 30: 122126, 130, 132–125.
  • 152
    Sheehan-Dare RA, Papworth-Smith J, Cunliffe WJ. A double-blind comparison of topical clindamycin and oral minocycline in the treatment of acne vulgaris. Acta Derm Venereol 1990; 70: 534537.
  • 153
    Katsambas A, Towarky AA, Stratigos J. Topical clindamycin phosphate compared with oral tetracycline in the treatment of acne vulgaris. Br J Dermatol 1987; 116: 387391.
  • 154
    Borglund E, Hagermark O, Nord CE. Impact of topical clindamycin and systemic tetracycline on the skin and colon microflora in patients with acne vulgaris. Scand J Infect Dis Suppl 1984; 43: 7681.
  • 155
    Hjorth N, Graupe K. Azelaic acid for the treatment of acne. A clinical comparison with oral tetracycline. Acta Derm Venereol Suppl (Stockh) 1989; 143: 4548.
  • 156
    Drake LA. Comparative efficacy and tolerance of Cleocin T topical gel (clindamycin phosphate topical gel) versus oral minocycline in the treatment of acne vulgaris. unpublished. 1980.
  • 157
    Peacock CE, Price C, Ryan BE, Mitchell AD. Topical clindamycin (Dalacin T(TM)) compared to oral minocycline (Minocin 50(TM)) in treatment of acne vulgaris. A randomized observer-blind controlled trial in three university student health centres. Clin Trials J 1990; 27: 219228.
  • 158
    Ozolins M, Eady EA, Avery A et al. Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne. Health Technol Assess 2005; 9: iii212.
  • 159
    Ozolins M, Eady EA, Avery AJ et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet 2004; 364: 21882195.
  • 160
    Bladon PT, Burke BM, Cunliffe WJ, Forster RA, Holland KT, King K. Topical azelaic acid and the treatment of acne: a clinical and laboratory comparison with oral tetracycline. Br J Dermatol 1986; 114: 493499.
  • 161
    Mareledwane NG. A randomized, open-label, comparative study of oral doxycycline 100 mg vs. 5% topical benzoyl peroxide in the treatment of mild to moderate acne vulgaris. Int J Dermatol 2006; 45: 14381439.
  • 162
    Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Arsonnaud S, Kang S. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed 2005; 4: 138146.
  • 163
    Cunliffe WJ, Meynadier J, Alirezai M et al. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. J Am Acad Dermatol 2003; 49: S218S226.
  • 164
    Gollnick HP, Graupe K, Zaumseil RP. Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne. Eur J Dermatol 2001; 11: 538544.
  • 165
    Oprica C, Emtestam L, Hagstromer L, Nord CE. Clinical and microbiological comparisons of isotretinoin vs. tetracycline in acne vulgaris. Acta Derm Venereol 2007; 87: 246254.
  • 166
    Dreno B, Moyse D, Alirezai M et al. Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris. Dermatology 2001; 203: 135140.
  • 167
    Cunliffe WJ, Burke B, Dodman B, Gould DJ. A double-blind trial of a zinc sulphate/citrate complex and tetracycline in the treatment of acne vulgaris. Br J Dermatol 1979; 101: 321325.
  • 168
    Carlborg L. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of a multicenter study. Acta Obstet Gynecol Scand Suppl 1986; 134: 2932.
  • 169
    Lachnit-Fixson U, Kaufmann J. [Therapy of androgenization symptoms: double blind study of an antiandrogen preparation (SH B 209 AB) against neogynon (author’s transl)]. Med Klin 1977; 72: 19221926.
  • 170
    Wishart JM. An open study of Triphasil and Diane 50 in the treatment of acne. Australas J Dermatol 1991; 32: 5154.
  • 171
    Vartiainen M, de Gezelle H, Broekmeulen CJ. Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate. Eur J Contracept Reprod Health Care 2001; 6: 4653.
  • 172
    Charoenvisal C, Thaipisuttikul Y, Pinjaroen S et al. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. Int J Fertil Menopausal Stud 1996; 41: 423429.
  • 173
    Dieben TO, Vromans L, Theeuwes A, Bennink HJ. The effects of CTR-24, a biphasic oral contraceptive combination, compared to Diane-35 in women with acne. Contraception 1994; 50: 373382.
  • 174
    Erkkola R, Hirvonen E, Luikku J, Lumme R, Mannikko H, Aydinlik S. Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms. Acta Obstet Gynecol Scand 1990; 69: 6165.
  • 175
    Worret I, Arp W, Zahradnik HP, Andreas JO, Binder N. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 2001; 203: 3844.
  • 176
    Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 2004; 74: 123130.
  • 177
    Winkler UH, Ferguson H, Mulders JA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. Contraception 2004; 69: 469476.
  • 178
    Rosen MP, Breitkopf DM, Nagamani M. A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris. Am J Obstet Gynecol 2003; 188: 11581160.
  • 179
    Palatsi R, Hirvensalo E, Liukko P et al. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives. Acta Derm Venereol 1984; 64: 517523.
  • 180
    Monk BE, Almeyda JA, Caldwell IW et al. Efficacy of low-dose cyproterone acetate compared with minocycline in the treatment of acne vulgaris. Clin Exp Dermatol 1987; 12: 319322.
  • 181
    Greenwood R, Brummitt L, Burke B, Cunliffe WJ. Acne: double blind clinical and laboratory trial of tetracycline, oestrogen-cyproterone acetate, and combined treatment. Br Med J (Clin Res Ed) 1985; 291: 12311235.
  • 182
    Papageorgiou P, Katsambas A, Chu A. Phototherapy with blue (415 nm) and red (660 nm) light in the treatment of acne vulgaris. Br J Dermatol 2000; 142: 973978.
  • 183
    Tzung TY, Wu KH, Huang ML. Blue light phototherapy in the treatment of acne. Photodermatol Photoimmunol Photomed 2004; 20: 266269.
  • 184
    Feucht CL, Allen BS, Chalker DK, Smith JG Jr. Topical erythromycin with zinc in acne. A double-blind controlled study. J Am Acad Dermatol 1980; 3: 483491.
  • 185
    Stainforth J, Macdonald-Hull S, Papworth-Smith JW et al. A single-blind comparison of topical erythromycin/zinc lotion and oral minocycline in the treatment of acne vulgaris. J Dermatolog Treat 1993; 4: 119122.
  • 186
    Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther 2005; 27: 13291342.
  • 187
    Garner SE, Eady EA, Popescu C, Newton J, Li WA. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev(Online). 2003; 1: CD002086.
  • 188
    Dunlap FE, Mills OH, Tuley MR, Baker MD, Plott RT. Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference. Br J Dermatol 1998; 139(Suppl 52): 1722.
  • 189
    Egan N, Loesche MC, Baker MM. Randomized, controlled, bilateral (split-face) comparison trial of the tolerability and patient preference of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis 2001; 68: 2024.
  • 190
    Peck GL, Olsen TG, Butkus D et al. Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J Am Acad Dermatol 1982; 6: 735745.
  • 191
    Strauss JS, Leyden JJ, Lucky AW et al. A randomized trial of the efficacy of a new micronized formulation versus a standard formulation of isotretinoin in patients with severe recalcitrant nodular acne. J Am Acad Dermatol 2001; 45: 187195.
  • 192
    Strauss JS, Rapini RP, Shalita AR et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 1984; 10: 490496.
  • 193
    Jones DH, King K, Miller AJ, Cunliffe WJ. A dose-response study of I3-cis-retinoic acid in acne vulgaris. Br J Dermatol 1983; 108: 333343.
  • 194
    King K, Jones DH, Daltrey DC, Cunliffe WJ. A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. Br J Dermatol 1982; 107: 583590.
  • 195
    van der Meeren HL, van der Schroeff JG, Stijnen T, van Duren JA, van der Dries HA, van Voorst Vader PC. Dose-response relationship in isotretinoin therapy for conglobate acne. Dermatologica 1983; 167: 299303.
  • 196
    Al Mishari MA. A study of isotretinoin (Roaccutan) in nodulocystic acne. Clin Trials J 1986; 23: 15.
  • 197
    Mandekou-Lefaki I, Delli F, Teknetzis A, Euthimiadou R, Karakatsanis G. Low-dose schema of isotretinoin in acne vulgaris. Int J Clin Pharmacol Res 2003; 23: 4146.
  • 198
    Plewig G, Gollnick H, Meigel W, Wokalek H. [13-cis retinoic acid in the oral therapy of acne conglobata. Results of a multi-center study]. Hautarzt 1981; 32: 634646.
  • 199
    Pigatto PD, Finzi AF, Altomare GF, Polenghi MM, Vergani C, Vigotti G. Isotretinoin versus minocycline in cystic acne: a study of lipid metabolism. Dermatologica 1986; 172: 154159.
  • 200
    Lester RS, Schachter GD, Light MJ. Isotretinoin and tetracycline in the management of severe nodulocystic acne. Int J Dermatol 1985; 24: 252257.
  • 201
    Dhir R, Gehi NP, Agarwal R, More YE. Oral isotretinoin is as effective as a combination of oral isotretinoin and topical anti-acne agents in nodulocystic acne. Indian J Dermatol Venereol Leprol 2008; 74: 187.
  • 202
    Simonart T, Dramaix M, De Maertelaer V. Efficacy of tetracyclines in the treatment of acne vulgaris: a review. Br J Dermatol 2008; 158: 208216.
  • 203
    Panzer JD, Poche W, Meek TJ, Derbes VJ, Atkinson W. Acne treatment: a comparative efficacy trial of clindamycin and tetracycline. Cutis 1977; 19: 109111.
  • 204
    Poulos ET, Tedesco FJ. Acne vulgaris: double-blind trial comparing tetracycline and clindamycin. Arch Dermatol 1976; 112: 974976.
  • 205
    Al-Mishari MA. Clinical and bacteriological evaluation of tetracycline and erythromycin in acne vulgaris. Clin Ther 1987; 9: 273280.
  • 206
    Brandt H, Attila P, Ahokas T et al. Erythromycin acistrate – an alternative oral treatment for acne. J Dermatolog Treat 1994; 5: 35.
  • 207
    Gammon WR, Meyer C, Lantis S, Shenefelt P, Reizner G, Cripps DJ. Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris. A double-blind study. J Am Acad Dermatol 1986; 14: 183186.
  • 208
    Association Mieux prescrire (Editeur scientifique). Moins d’effets indésirables avec la doxycycline qu’avec la minocycline. Rev Prescrire 2009; 29: 354.
  • 209
    Ochsendorf F. Minocycline in acne vulgaris: benefits and risks. Am J Clin Dermatol 2010; 11: 327341.
  • 210
    Layton AM, Cunliffe WJ. Phototoxic eruptions due to doxycycline – a dose-related phenomenon. Clin Exp Dermatol 1993; 18: 425427.
  • 211
    Lim DS, Murphy GM. High-level ultraviolet A photoprotection is needed to prevent doxycycline phototoxicity: lessons learned in East Timor. Br J Dermatol 2003; 149: 213214.
  • 212
    Bjellerup M, Ljunggren B. Differences in phototoxic potency should be considered when tetracyclines are prescribed during summer-time. A study on doxycycline and lymecycline in human volunteers, using an objective method for recording erythema. Br J Dermatol 1994; 130: 356360.
  • 213
    European Directive for systemic isotretinoin prescription. EMEA – Committee for Proprietary Medicinal Products (CPMP). [WWW document]. URL http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Isotretinoin_29/WC500010882.pdf (last accessed: 6 January 2012), 2003.
  • 214
    Ganceviciene R, Zouboulis CC. Isotretinoin: state of the art treatment for acne vulgaris. J Dtsch Dermatol Ges 2010; 8(Suppl 1): S47S59.
  • 215
    Layton AM, Cunliffe WJ. Guidelines for optimal use of isotretinoin in acne. J Am Acad Dermatol 1992; 27: S2S7.
  • 216
    Strauss JS, Krowchuk DP, Leyden JJ et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007; 56: 651663.
  • 217
    Cunliffe WJ, van de Kerkhof PC, Caputo R et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997; 194: 351357.
  • 218
    Layton AM. Optimal management of acne to prevent scarring and psychological sequelae. Am J Clin Dermatol 2001; 2: 135141.
  • 219
    Rubinow DR, Peck GL, Squillace KM, Gantt GG. Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin. J Am Acad Dermatol 1987; 17: 2532.
  • 220
    Layton AM, Dreno B, Gollnick HPM, Zouboulis CC. A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol 2006; 20: 773776.
  • 221
    Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg 2007; 26: 210220.
  • 222
    Ross JI, Snelling AM, Eady EA et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol 2001; 144: 339346.
  • 223
    Ross JI, Snelling AM, Carnegie E et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003; 148: 467478.
  • 224
    Eady EA, Cove JH. Topical antibiotic therapy: current status and future prospects. Drugs Exp Clin Res 1990; 16: 423433.
  • 225
    Oprica C, Nord CE, Bacteria ESGoARiA. European surveillance study on the antibiotic susceptibility of Propionibacterium acnes. Clin Microbiol Infect 2005; 11: 204213.
  • 226
    Nord CE, Oprica C. Antibiotic resistance in Propionibacterium acnes. Microbiological and clinical aspects. Anaerobe 2006; 12: 207210.
  • 227
    Eady EA. Bacterial resistance in acne. Dermatology 1998; 196: 5966.
  • 228
    Levy RM, Huang EY, Roling D, Leyden JJ, Margolis DJ. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol 2003; 139: 467471.
  • 229
    Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 121: 5157.
  • 230
    Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol 2005; 153: 395403.
  • 231
    Cunliffe WJ, Forster RA, Greenwood ND et al. Tetracycline and acne vulgaris: a clinical and laboratory investigation. Br Med J 1973; 4: 332335.
  • 232
    Bettoli V, Mantovani L, Borghi A. Adapalene 0.1% Cream after Oral Isotretinoin: Evaluation of the Acne Recurrence Incidence. 15th Annual EADV Congress. Rhodes. Medimond International Proceedings, Bologna, Italy, 2006.
  • 233
    Thiboutot DM, Shalita AR, Yamauchi PS et al. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol 2006; 142: 597602.
  • 234
    Zhang JZ, Li LF, Tu YT, Zheng J. A successful maintenance approach in inflammatory acne with adapalene gel 0.1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1%. J Dermatolog Treat 2004; 15: 372378.
  • 235
    Alirezai M, George SA, Coutts I et al. Daily treatment with adapalene gel 0.1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline. Eur J Dermatol 2007; 17: 4551.
  • 236
    Graupe K, Cunliffe WJ, Gollnick HP, Zaumseil RP. Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports. Cutis 1996; 57: 2035.
  • 237
    Goltz RW, Coryell GM, Schnieders JR, Neidert GL. A comparison of Cleocin T 1 percent solution and Cleocin T 1 percent lotion in the treatment of acne vulgaris. Cutis 1985; 36: 265268.
  • 238
    Parker F. A comparison of clindamycin 1% solution versus clindamycin 1% gel in the treatment of acne vulgaris. Int J Dermatol 1987; 26: 121122.
  • 239
    Leyden JJ, Shalita AR, Saatjian GD, Sefton J. Erythromycin 2% gel in comparison with clindamycin phosphate 1% solution in acne vulgaris. J Am Acad Dermatol 1987; 16: 822827.
  • 240
    Mills OH, Berger RS, Kligman AM, McElroy JA, Di Matteo J. A comparative study of Erycette(TM) vs Cleocin-T(TM). Adv Ther 1992; 9: 1420.
  • 241
    Thomas DR, Raimer S, Smith EB. Comparison of topical erythromycin 1.5 percent solution versus topical clindamycin phosphate 1.0 percent solution in the treatment of acne vulgaris. Cutis 1982; 29: 624625, 628–632.
  • 242
    Shahlita AR, Smith EB, Bauer E. Topical erythromycin v clindamycin therapy for acne. A multicenter, double-blind comparison. Arch Dermatol 1984; 120: 351355.
  • 243
    Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a double-blind, phase III comparison study versus erythromycin 2% cream. Eur J Dermatol 2006; 16: 4855.
  • 244
    Patel VB, Misra AN, Marfatia YS. Preparation and comparative clinical evaluation of liposomal gel of benzoyl peroxide for acne. Drug Dev Ind Pharm 2001; 27: 863869.
  • 245
    Cunliffe WJ, Holland KT. The effect of benzoyl peroxide on acne. Acta Derm Venereol 1981; 61: 267269.
  • 246
    Fyrand O, Jakobsen HB. Water-based versus alcohol-based benzoyl peroxide preparations in the treatment of acne vulgaris. Dermatologica 1986; 172: 263267.
  • 247
    Patel VB, Misra A, Marfatia YS. Topical liposomal gel of tretinoin for the treatment of acne: research and clinical implications. Pharm Dev Technol 2000; 5: 455464.
  • 248
    Schafer-Korting M, Korting HC, Ponce-Poschl E. Liposomal tretinoin for uncomplicated acne vulgaris. Clin Investig 1994; 72: 10861091.
  • 249
    Berger R, Rizer R, Barba A et al. Tretinoin gel microspheres 0.04% versus 0.1% in adolescents and adults with mild to moderate acne vulgaris: a 12-week, multicenter, randomized, double-blind, parallel-group, phase IV trial. Clin Ther 2007; 29: 10861097.
  • 250
    Thiboutot D, Jarratt M, Rich P, Rist T, Rodriguez D, Levy S. A randomized, parallel, vehicle-controlled comparison of two erythromycin/benzoyl peroxide preparations for acne vulgaris. Clin Ther 2002; 24: 773785.
  • 251
    Schachner L, Eaglstein W, Kittles C, Mertz P. Topical erythromycin and zinc therapy for acne. J Am Acad Dermatol 1990; 22: 253260.
  • 252
    Dhawan SS. Comparison of 2 clindamycin 1%-benzoyl peroxide 5% topical gels used once daily in the management of acne vulgaris. Cutis 2009; 83: 265272.
  • 253
    Kircik L. Community-based trial results of combination clindamycin 1%--benzoyl peroxide 5% topical gel plus tretinoin microsphere gel 0.04% or 0.1% or adapalene gel 0.1% in the treatment of moderate to severe acne. Cutis 2007; 80: 1014.
  • 254
    Kircik LH. Comparative efficacy and safety results of two topical combination acne regimens. J Drugs Dermatol 2009; 8: 624630.
  • 255
    Cunliffe WJ, Fernandez C, Bojar R, Kanis R, West F. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. J Dermatolog Treat 2005; 16: 213218.
  • 256
    Del Rosso J. Study results of benzoyl peroxide 5%/clindamycin. J Drugs Dermatol 2007; 6: 616622.
  • 257
    Shalita AR, Rafal ES, Anderson DN, Yavel R, Landow S, Lee WL. Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide 6% cleanser for the treatment of acne vulgaris. Cutis 2003; 72: 167172.
  • 258
    Wolf JE Jr, Kaplan D, Kraus SJ et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol 2003; 49: S211S217.
  • 259
    NilFroushzadeh MA, Siadat AH, Baradaran EH, Moradi S. Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to moderate acne vulgaris: a randomized control trial. Indian J Dermatol Venereol Leprol 2009; 75: 279282.
  • 260
    Cambazard F. Clinical efficacy of Velac, a new tretinoin and clindamycin phosphate gel in acne vulgaris. J Eur Acad Dermatol Venereol 1998; 11(Suppl 1): S20S27; discussion S28-29.
  • 261
    Zouboulis CC, Derumeaux L, Decroix J, Maciejewska-Udziela B, Cambazard F, Stuhlert A. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol 2000; 143: 498505.
  • 262
    Richter JR, Forstrom LR, Kiistala UO, Jung EG. Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne. J Eur Acad Dermatol Venereol 1998; 11: 227233.
  • 263
    Ko HC, Song M, Seo SH, Oh CK, Kwon KS, Kim MB. Prospective, open-label, comparative study of clindamycin 1%/benzoyl peroxide 5% gel with adapalene 0.1% gel in Asian acne patients: efficacy and tolerability. J Eur Acad Dermatol Venereol 2009; 23: 245250.
  • 264
    Langner A, Chu A, Goulden V, Ambroziak M. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. Br J Dermatol 2008; 158: 122129.
  • 265
    Gupta AK, Lynde CW, Kunynetz RA, Amin S, Choi K, Goldstein E. A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. J Cutan Med Surg 2003; 7: 3137.
  • 266
    Marazzi P, Boorman GC, Donald AE, Davies HD. Clinical evaluation of double strength isotrexin versus benzamycin in the topical treatment of mild to moderate acne vulgaris. J Dermatolog Treat 2002; 13: 111117.
  • 267
    Chu A, Huber FJ, Plott RT. The comparative efficacy of benzoyl peroxide 5%/erythromycin 3% gel and erythromycin 4%/zinc 1.2% solution in the treatment of acne vulgaris. Br J Dermatol 1997; 136: 235238.
  • 268
    Packman AM, Brown RH, Dunlap FE, Kraus SJ, Webster GF. Treatment of acne vulgaris: combination of 3% erythromycin and 5% benzoyl peroxide in a gel compared to clindamycin phosphate lotion. Int J Dermatol 1996; 35: 209211.
  • 269
    Schachner L, Pestana A, Kittles C. A clinical trial comparing the safety and efficacy of a topical erythromycin-zinc formulation with a topical clindamycin formulation. J Am Acad Dermatol 1990; 22: 489495.
  • 270
    Bowman S, Gold M, Nasir A, Vamvakias G. Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. J Drugs Dermatol 2005; 4: 611618.
  • 271
    Langner A, Sheehan-Dare R, Layton A. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. J Eur Acad Dermatol Venereol 2007; 21: 311319.
  • 272
    Christian GL, Krueger GG. Clindamycin vs placebo as adjunctive therapy in moderately severe acne. Arch Dermatol 1975; 111: 9971000.
  • 273
    Plewig G, Petrozzi JW, Berendes U. Double-blind study of doxycycline in acne vulgaris. Arch Dermatol 1970; 101: 435438.
  • 274
    Fleischer AB Jr, Dinehart S, Stough D, Plott RT. Safety and efficacy of a new extended-release formulation of minocycline. Cutis 2006; 78: 2131.
  • 275
    Olafsson JH, Gudgeirsson J, Eggertsdottir GE, Kristjansson F. Doxycycline versus minocycline in the treatment of acne vulgaris: a double-blind study. J Dermatolog Treat 1989; 1: 1517.
  • 276
    Cunliffe WJ, Grosshans E, Belaich S, Meynadier J, Alirezai M, Thomas L. A comparison of the efficacy and safety of lymecycline and minocycline in patients with moderately severe acne vulgaris. Eur J Dermatol 1998; 8: 161166.
  • 277
    Bossuyt L, Bosschaert J, Richert B et al. Lymecycline in the treatment of acne: an efficacious, safe and cost-effective alternative to minocycline. Eur J Dermatol 2003; 13: 130135.
  • 278
    Cullen SI, Cohan RH. Minocycline therapy in acne vulgaris. Cutis 1976; 17: 12081210, 1214.
  • 279
    Ruping KW, Tronnier H. Acne therapy: Results of a multicentre study with minocyline. R Soc Med Serv Int Cong Symp Ser 1985; 95: 109119.
  • 280
    Dreno B, Amblard P, Agache P, Sirot S, Litoux P. Low doses of zinc gluconate for inflammatory acne. Acta Derm Venereol 1989; 69: 541543.
  • 281
    Orris L, Shalita AR, Sibulkin D, London SJ, Gans EH. Oral zinc therapy of acne. Absorption and clinical effect. Arch Dermatol 1978; 114: 10181020.
  • 282
    Weimar VM, Puhl SC, Smith WH, tenBroeke JE. Zinc sulfate in acne vulgaris. Arch Dermatol 1978; 114: 17761778.
  • 283
    Vena GA. Comparison of two different dosing regimens with lymecycline, in association with adapalene, in inflammatory acne. Eur J Inflamm 2005; 3: 8995.
  • 284
    Leyden J, Shalita A, Hordinsky M, Swinyer L, Stanczyk FZ, Weber ME. Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: a randomized, placebo-controlled trial. J Am Acad Dermatol 2002; 47: 399409.
  • 285
    Thiboutot D, Archer DF, Lemay A, Washenik K, Roberts J, Harrison DD. A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. Fertil Steril 2001; 76: 461468.
  • 286
    Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997; 37: 746754.
  • 287
    Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997; 89: 615622.
  • 288
    Plewig G, Cunliffe WJ, Binder N, Hoschen K. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial. Contraception 2009; 80: 2533.
  • 289
    Koltun W, Lucky AW, Thiboutot D et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 2008; 77: 249256.
  • 290
    Maloney JM, Dietze P Jr, Watson D et al. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol 2008; 112: 773781.
  • 291
    Fugere P, Percival-Smith RK, Lussier-Cacan S, Davignon J, Farquhar D. Cyproterone acetate/ethinyl estradiol in the treatment of acne. A comparative dose-response study of the estrogen component. Contraception 1990; 42: 225234.
  • 292
    Halbe HW, de Melo NR, Bahamondes L et al. Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene. Eur J Contracept Reprod Health Care 1998; 3: 113120.
  • 293
    Koetsawang S, Charoenvisal C, Banharnsupawat L, Singhakovin S, Kaewsuk O, Punnahitanont S. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women. Contraception 1995; 51: 225229.
  • 294
    Mango D, Ricci S, Manna P, Miggiano GA, Serra GB. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. Contraception 1996; 53: 163170.
  • 295
    Graupe K, Zaumseil RP. Skinoren – a new local therapeutic agent for the treatment of acne vulgaris. In Macher E, Kolde G, Bröcker EB, eds. Jahrbuch der Dermatologie. Biermann, Zülpich, 1991: 159169.
  • 296
    Stoughton RB, Resh W. Topical clindamycin in the control of acne vulgaris. Cutis 1976; 17: 551554.
  • 297
    Padilla RS, McCabe JM, Becker LE. Topical tetracycline hydrochloride vs. topical clindamycin phosphate in the treatment of acne: a comparative study. Int J Dermatol 1981; 20: 445448.
  • 298
    Robledo AA, Lopez BE, del Pino GJ et al. Multicentric comparative study of the efficacy and tolerance of clindamycin phosphate 1% topical solution and tetracycline topical solution for the treatment of acne vulgaris. Curr Ther Res Clin Exp 1988; 43: 2126.
  • 299
    Yong CC. Benzoyl peroxide gel therapy in acne in Singapore. Int J Dermatol 1979; 18: 485488.
  • 300
    Strauss JS, Stranieri AM. Acne treatment with topical erythromycin and zinc: effect of Propionibacterium acnes and free fatty acid composition. J Am Acad Dermatol 1984; 11: 8689.
  • 301
    Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate. J Am Acad Dermatol 2006; 54: 647651.
  • 302
    Skidmore R, Kovach R, Walker C et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003; 139: 459464.
  • 303
    Dubertret L, Alirezai M, Rostain G et al. The use of lymecycline in the treatment of moderate to severe acne vulgaris: a comparison of the efficacy and safety of two dosing regimens. Eur J Dermatol 2003; 13: 4448.
  • 304
    Stewart DM, Torok HM, Weiss JS, Plott RT. Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris. Cutis 2006; 78: 1120.
  • 305
    Hersle K, Gisslen H. Minocycline in acne vulgaris: a double-blind study. Curr Ther Res Clin Exp 1976; 19: 339342.
  • 306
    Lane P, Williamson DM. Treatment of acne vulgaris with tetracycline hydrochloride: a double-blind trial with 51 patients. Br Med J 1969; 2: 7679.
  • 307
    Stewart WD, Maddin S, Nelson AJ, Danto JL. Therapeutic agents in acne vulgaris. I. Tetracycline. Can Med Assoc J 1963; 89: 10961097.
  • 308
    Wong RC, Kang S, Heezen JL, Voorhees JJ, Ellis CN. Oral ibuprofen and tetracycline for the treatment of acne vulgaris. J Am Acad Dermatol 1984; 11: 10761081.
  • 309
    Toossi P, Farshchian M, Malekzad F, Mohtasham N, Kimyai-Asadi A. Subantimicrobial-dose doxycycline in the treatment of moderate facial acne. J Drugs Dermatol 2008; 7: 11491152.
  • 310
    Bleeker J, Hellgren L, Vincent J. Effect of systemic erythromycin stearate on the inflammatory lesions and skin surface fatty acids in acne vulgaris. Dermatologica 1981; 162: 342349.
  • 311
    Bleeker J. Tolerance and efficacy of erythromycin stearate tablets versus enteric-coated erythromycin base capsules in the treatment of patients with acne vulgaris. J Int Med Res 1983; 11: 3841.
  • 312
    Pierard-Franchimont C, Goffin V, Arrese JE et al. Lymecycline and minocycline in inflammatory acne: a randomized, double-blind intent-to-treat study on clinical and in vivo antibacterial efficacy. Skin Pharmacol Appl Skin Physiol 2002; 15: 112119.
  • 313
    Hubbell CG, Hobbs ER, Rist T, White JW Jr. Efficacy of minocycline compared with tetracycline in treatment of acne vulgaris. Arch Dermatol 1982; 118: 989992.
  • 314
    Khanna N. Treatment of acne vulgaris with oral tetracyclines. Indian J Dermatol Venereol Leprol 1993; 29: 7476.
  • 315
    Samuelson JS. An accurate photographic method for grading acne: initial use in a double-blind clinical comparison of minocycline and tetracycline. J Am Acad Dermatol 1985; 12: 461467.
  • 316
    Akman A, Durusoy C, Senturk M, Koc CK, Soyturk D, Alpsoy E. Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study. Arch Dermatol Res 2007; 299: 467473.
  • 317
    Kapadia N. Comparative efficacy and safety and efficacy of systemic 13-cis retinoic acid 20 mg/day vs 40 mg/day in acne vulgaris. J Pak Assoc Dermatolog 2005; 15: 238241.
  • 318
    Hillstrom L, Pettersson L, Hellbe L, Kjellin A, Leczinsky CG, Nordwall C. Comparison of oral treatment with zinc sulphate and placebo in acne vulgaris. Br J Dermatol 1977; 97: 681684.
  • 319
    Göransson K, Liden S, Odsell L. Oral zinc in acne vulgaris: a clinical and methodological study. Acta Derm Venereol 1978; 58: 443448.
  • 320
    Liden S, Goransson K, Odsell L. Clinical evaluation in acne. Acta Derm Venereol Suppl (Stockh) 1980; Suppl. 89: 4752.
  • 321
    Verma KC, Saini AS, Dhamija SK. Oral zinc sulphate therapy in acne vulgaris: a double-blind trial. Acta Derm Venereol 1980; 60: 337340.
  • 322
    Weismann K, Wadskov S, Sondergaard J. Oral zinc sulphate therapy for acne vulgaris. Acta Derm Venereol 1977; 57: 357360.
  • 323
    Harrison PV. A comparison of doxycycline and minocycline in the treatment of acne vulgaris. Clin Exp Dermatol 1988; 13: 242244.
  • 324
    Burton J. A placebo-controlled study to evaluate the efficacy of topical tetracycline and oral tetracycline in the treatment of mild to moderate acne. Dermatology Research Group. J Int Med Res 1990; 18: 94103.
  • 325
    Palombo-Kinne E, Schellschmidt I, Schumacher U, Graser T. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate. Contraception 2009; 79: 282289.
  • 326
    Gruber DM, Sator MO, Joura EA, Kokoschka EM, Heinze G, Huber JC. Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial. Arch Dermatol 1998; 134: 459463.
  • 327
    Katz HI, Kempers S, Akin MD, Dunlap F, Whiting D, Norbart TC. Effect of a desogestrel-containing oral contraceptive on the skin. Eur J Contracept Reprod Health Care 2000; 5: 248255.
  • 328
    Kranzlin HT, Nap MA. The effect of a phasic oral contraceptive containing Desogestrel on seborrhea and acne. Eur J Contracept Reprod Health Care 2006; 11: 613.
  • 329
    Colver GB, Mortimer PS, Dawber RP. Cyproterone acetate and two doses of oestrogen in female acne; a double-blind comparison. Br J Dermatol 1988; 118: 9599.
  • 330
    Miller JA, Wojnarowska FT, Dowd PM et al. Anti-androgen treatment in women with acne: a controlled trial. Br J Dermatol 1986; 114: 705716.
  • 331
    Hongcharu W, Taylor CR, Chang Y, Aghassi D, Suthamjariya K, Anderson RR. Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol 2000; 115: 183192.
  • 332
    Horfelt C, Stenquist B, Halldin CB, Ericson MB, Wennberg AM. Single low-dose red light is as efficacious as methyl-aminolevulinate – photodynamic therapy for treatment of acne: clinical assessment and fluorescence monitoring. Acta Derm Venereol 2009; 89: 372378.
  • 333
    Horfelt C, Funk J, Frohm-Nilsson M, Wiegleb Edstrom D, Wennberg AM. Topical methyl aminolaevulinate photodynamic therapy for treatment of facial acne vulgaris: results of a randomized, controlled study. Br J Dermatol 2006; 155: 608613.
  • 334
    Na JI, Suh DH. Red light phototherapy alone is effective for acne vulgaris: randomized, single-blinded clinical trial. Dermatol Surg 2007; 33: 12281233; discussion 1233.
  • 335
    Pollock B, Turner D, Stringer MR et al. Topical aminolaevulinic acid-photodynamic therapy for the treatment of acne vulgaris: a study of clinical efficacy and mechanism of action. Br J Dermatol 2004; 151: 616622.
  • 336
    Gold MH, Rao J, Goldman MP et al. A multicenter clinical evaluation of the treatment of mild to moderate inflammatory acne vulgaris of the face with visible blue light in comparison to topical 1% clindamycin antibiotic solution. J Drugs Dermatol 2005; 4: 6470.
  • 337
    Sami NA, Attia AT, Badawi AM. Phototherapy in the treatment of acne vulgaris. J Drugs Dermatol 2008; 7: 627632.
  • 338
    Haedersdal M, Togsverd-Bo K, Wiegell SR, Wulf HC. Long-pulsed dye laser versus long-pulsed dye laser-assisted photodynamic therapy for acne vulgaris: a randomized controlled trial. J Am Acad Dermatol 2008; 58: 387394.
  • 339
    Jung JY, Choi YS, Yoon MY, Min SU, Suh DH. Comparison of a pulsed dye laser and a combined 585/1,064-nm laser in the treatment of acne vulgaris. Dermatol Surg 2009; 35: 11811187.
  • 340
    Leheta TM. Role of the 585-nm pulsed dye laser in the treatment of acne in comparison with other topical therapeutic modalities. J Cosmet Laser Ther 2009; 11: 118124.
  • 341
    Orringer JS, Kang S, Hamilton T et al. Treatment of acne vulgaris with a pulsed dye laser: a randomized controlled trial. JAMA 2004; 291: 28342839.
  • 342
    Seaton ED, Charakida A, Mouser PE, Grace I, Clement RM, Chu AC. Pulsed-dye laser treatment for inflammatory acne vulgaris: randomised controlled trial. Lancet 2003; 362: 13471352.
  • 343
    Bowes LE, Manstein D, Rox Andersen R. Effects of 532 nm KTP laser exposure on acne and sebaceous glands. Lasers Med Sci 2003; 18: S6S7.
  • 344
    Baugh WP, Kucaba WD. Nonablative phototherapy for acne vulgaris using the KTP 532 nm laser. Dermatol Surg 2005; 31: 12901296.
  • 345
    Oh SH, Ryu DJ, Han EC, Lee KH, Lee JH. A comparative study of topical 5-aminolevulinic acid incubation times in photodynamic therapy with intense pulsed light for the treatment of inflammatory acne. Dermatol Surg 2009; 35: 19181926.
  • 346
    Rojanamatin J, Choawawanich P. Treatment of inflammatory facial acne vulgaris with intense pulsed light and short contact of topical 5-aminolevulinic acid: a pilot study. Dermatol Surg 2006; 32: 991996; discussion 996–997.
  • 347
    Santos MA, Belo VG, Santos G. Effectiveness of photodynamic therapy with topical 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone in the treatment of acne vulgaris: comparative study. Dermatol Surg 2005; 31: 910915.
  • 348
    Paithankar DY, Ross EV, Saleh BA, Blair MA, Graham BS. Acne treatment with a 1,450 nm wavelength laser and cryogen spray cooling. Lasers Surg Med 2002; 31: 106114.
  • 349
    Uebelhoer NS, Bogle MA, Dover JS, Arndt KA, Rohrer TE. Comparison of stacked pulses versus double-pass treatments of facial acne with a 1,450-nm laser. Dermatol Surg 2007; 33: 552559.
  • 350
    Wang SQ, Counters JT, Flor ME, Zelickson BD. Treatment of inflammatory facial acne with the 1,450 nm diode laser alone versus microdermabrasion plus the 1,450 nm laser: a randomized, split-face trial. Dermatol Surg 2006; 32: 249255; discussion 255.
  • 351
    Orringer JS, Kang S, Maier L et al. A randomized, controlled, split-face clinical trial of 1320-nm Nd:YAG laser therapy in the treatment of acne vulgaris. J Am Acad Dermatol 2007; 56: 432438.
  • 352
    Orringer JS, Sachs DL, Bailey E, Kang S, Hamilton T, Voorhees JJ. Photodynamic therapy for acne vulgaris: a randomized, controlled, split-face clinical trial of topical aminolevulinic acid and pulsed dye laser therapy. J Cosmet Dermatol 2010; 9: 2834.
  • 353
    Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using methyl aminolaevulinate: a blinded, randomized, controlled trial. Br J Dermatol 2006; 154: 969976.
  • 354
    Horfelt C, Stenquist B, Larko O, Faergemann J, Wennberg AM. Photodynamic therapy for acne vulgaris: a pilot study of the dose-response and mechanism of action. Acta Derm Venereol 2007; 87: 325329.
  • 355
    Thorneycroft IH, Stanczyk FZ, Bradshaw KD, Ballagh SA, Nichols M, Weber ME. Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception 1999; 60: 255262.
  • 356
    Gerlinger C, Städtler G, Götzelmann R, Graupe K, Endrikat J. A non-inferiority margin for acne lesion counts. Drug Information J 2008; 42: 607615.